-
-
-
-
-
-
-
Morgan Stanley on Zai Lab (ZLAB) Post BMY (BMY) Approval: 'We believe it should bode moderately positively for ZLAB shares'
-
-
-
-
-
-
-
Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA
-
-
-
-
-
-
-
Zai Lab Announces First Quarter 2021 Financial Results
-
-
-
-
-
-
-
MacroGenics (MGNX) Provides Update on Corporate Progress and 2019 Financial Results
-
-
-
-
-
-
-
Zai Lab Announces First Patients Treated in Separate Phase 1b and Registrational Bridging Studies
-
-
-
-
-
-
-
Paratek Pharmaceuticals (PRTK) Confirms Positive FDA Ad Comm Recommendation for Omadacycline
-
-
-
-
-
-
-
Paratek’s New Drug Applications for Oral and Intravenous Omadacycline Accepted for Priority Review by FDA
-
15,695 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

